New-onset systemic lupus erythematosus following BNT162b2 mRNA COVID-19 vaccine: a case series and literature review

Rheumatol Int. 2022 Dec;42(12):2261-2266. doi: 10.1007/s00296-022-05203-3. Epub 2022 Sep 13.

Abstract

Emerging data evaluated the possible link between the Coronavirus 19 (COVID-19) vaccine and acute flares of rheumatic autoimmune diseases. However, the association between the COVID-19 vaccine and the development of de-novo rheumatic autoimmune diseases remained unclear. We report the first case series of three male patients who developed new-onset systemic lupus erythematosus following receiving Pfizer BNT162b2 mRNA vaccination. The clinical characteristics share some similarities with drug-induced lupus. More patients with SLE following COVID-19 may be diagnosed in the future. Additional studies will provide more significant insights into the possible immunogenic influence of the COVID-19 vaccine.

Keywords: COVID-19; Systemic lupus erythematosus; Vaccine.

Publication types

  • Review

MeSH terms

  • Autoimmune Diseases*
  • BNT162 Vaccine
  • COVID-19 Vaccines* / adverse effects
  • COVID-19* / prevention & control
  • Humans
  • Lupus Erythematosus, Systemic* / diagnosis
  • Male
  • RNA, Messenger
  • Vaccination

Substances

  • COVID-19 Vaccines
  • RNA, Messenger
  • BNT162 Vaccine